Cancer Network
ASCO 2016 Ovarian Cancer, Gynecologic Cancers, Ovarian Cancer
Despite
hematologic toxicities and port-related adverse events, IP carboplatin
plus IV dose-dense paclitaxel appears to be effective in patients with
suboptimally debulked epithelial ovarian or primary peritoneal
carcinoma.
Baseline
quality of life measures predict early cessation of chemotherapy and
overall survival in women with platinum-resistant/refractory, recurrent
ovarian cancer.
Extending
platinum-free interval with pegylated liposomal doxorubicin, topotecan,
or gemcitabine does not improve overall survival among patients with
recurrent ovarian cancer.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.